Rising JCV-Ab index during natalizumab therapy for MS: Inauspicious for a highly efficacious drug.
Rising JCV-Ab index during natalizumab therapy for MS: Inauspicious for a highly efficacious drug. Neurol Neuroimmunol Neuroinflamm. 2016 Feb; 3(1):e199.